logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5662.produseast1
Showing 1 - 3 of 3 Items
Showing 1 - 3 of 3 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Genomic surveillance of SARS-CoV-2 reveals highest severity and mortality of delta over other variants: evidence from Cameroon

Fokam J, Essomba RG, Njouom R, Okomo MCA, Eyangoh S,  et al.
2023-12-08 • Scientific Reports
2023-12-08 • Scientific Reports
While the SARS-CoV-2 dynamic has been described globally, there is a lack of data from Sub-Saharan Africa. We herein report the dynamics of SARS-CoV-2 lineages from March 2020 to March 2...
Journal Article
|
Research
Journal Article
|
Research

Mutational correlates of virological failure in individuals receiving a WHO-recommended tenofovir-containing first-line regimen: Aa international collaboration

Rhee SY, Varghese B, Holmes SP, Van Zyl GU, Steegen K,  et al.
2017-03-19 • EBioMedicine
2017-03-19 • EBioMedicine
Tenofovir disoproxil fumarate (TDF) genotypic resistance defined by K65R/N and/or K70E/Q/G occurs in 20% to 60% of individuals with virological failure (VF) on a WHO-recommended TDF-cont...

Doing no harm? Adverse events in a nation-wide cohort of patients with multidrug-resistant tuberculosis in Nigeria

Avong YK, Isaakidis P, Hinderaker SG, Van der Bergh R, Ali E,  et al.
2015-03-17 • PLOS One
2015-03-17 • PLOS One
Adverse events (AEs) of second line anti-tuberculosis drugs (SLDs) are relatively well documented. However, the actual burden has rarely been described in detail in programmatic settings...